Formulation and evaluation of lecithin organogel for treatment of arthritis

 
 
 
  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract


    Background: Arthritis is a disease of the joint that involves inflammation of one or more joints. Topical administration of NSAIDs could deliver lornoxicam to the site of action in rheumatic diseases, which would reduce the gastrointestinal complications and side effects of the drug.

    Methods: In this method, the oily phase was prepared by dispersing the specific amount (ratio; 40:60) of purified lecithin at room temperature in isopropyl myristate as dispersing and emulsifying agent. The aqueous phase of polypropylene was prepared by dispersing a weighed amount of polypropylene and glycerol in water. It was stored at 2-4 oC overnight for the effective dissolution. The aqueous phase was slowly added in oily phase with stirring at 400 rpm using a mechanical stirrer. The prepared organogel of lornoxicam were evaluated for its appearance, organoleptic characteristic, viscosity, gelation temperature, drug content and in vitro release study. In vivo evaluation for analgesic activity of formulation was carried out in terms of skin irritation study, hot plate method; writhing test and edema paw induce method.

    Results: The drug content of organogel formulations was found in the range of 92.43±2.10-97.93±0.31% indicating uniform distribution of drug through the base and no interaction of drug with component of base. Posthoc Dunnet’s t-test by employing statistical software, GraphPad InStat 3. It’s shown differences between groups were considered significant at P < 0.05.

    Conclusion: The transdermal organogel formulation of lornoxicam could provide significant anti-inflammatory and antirheumatic activity when applied topically and was observed to be functional for topical delivery of lornoxicam.


  • Keywords


    Lornoxicam; Lecithin; Organogel; Arthritis; Topical Delivery; NSAIDS.

  • References


      [1] Rosenow D. A comparison of patientcontrolled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery. Anesthesia & Analgesia (International Anesthesia Research Society), 1998; 86: 1045-1050.

      [2] Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol Today. 2000; 3:318–26. http://dx.doi.org/10.1016/S1461-5347(00)00295-9.

      [3] Idson B, Lazarus J. Semisolids. In: The theory and practice of industrial pharmacy. Bombay, India: Vargehese Publishing House; 1991. p. 534–63.

      [4] Bhatia A, Singh B, Amarji B, Katare OP. Tamoxifen-Loaded liposomal topical formulation arrests hair growth in mice. Br J Dermatol Nurs. 2009.

      [5] Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B, et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candiasis. J Liposome Res. 2010; 20 (4):341–50. http://dx.doi.org/10.3109/08982101003596125.

      [6] Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S, et al. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res. 2010; 20 (1):38–48. http://dx.doi.org/10.3109/08982100903030263.

      [7] Puglia C, Filosa R, Peduto A, de Caprariis P, Rizza L, Bonina F, et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS PharmSciTech. 2006; 7 (3):E1–9. http://dx.doi.org/10.1208/pt070364.

      [8] Ferderber K, Hook S, Rades T. Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery. J Liposome Res. 2009; 19(4):267–77. http://dx.doi.org/10.3109/08982100902814006.

      [9] Luciana BL, Hillary VDW, Hsin TL, Vijay V, Hsin KL, and Stan N, et al. Topical delivery of lycopene using microemulsions: enhanced skin penetration and tissue antioxidant activity. J Pharm Sci. 2009; 99(3):1346–57.

      [10] Scalia S, Mezzena M, Iannuccelli V. Influence of solid lipid microparticle carriers on skin penetration of the sunscreen agent, 4-methylbenzylidene camphor. J Pharm Pharmacol .2007; 59:1621–7. http://dx.doi.org/10.1211/jpp.59.12.0003.

      [11] Jain SK, Gupta Y, Jain A, Rai K. Enhanced transdermal delivery of acyclovir sodium via elastic liposomes. Drug Deliv. 2006; 15:141–7. http://dx.doi.org/10.1080/10717540801952407.

      [12] Maestrelli F, Capasso G, González-Rodríguez ML, Antonio M, Rabasco CG, Mura P. Effect of preparation technique on the properties and in vivo efficacy of benzocaine-loaded ethosomes. J Liposome Res. 2009; 19 (4):253–60. http://dx.doi.org/10.3109/08982100902788408.

      [13] Bendas ER, Tadros MI. Enhanced Transdermal Delivery of Salbutamol Sulfate via Ethosomes. AAPS PharmSciTech 2007; 8 (4) Article 107 http://dx.doi.org/10.1208/pt0804107.

      [14] Bender J, Simonsson C, Smedh M, Engström S, Ericson MB. Lipid cubic phases in topical drug delivery: visualization of skin distribution using two-photon microscopy. J Control Release. 2008; 129 (3):163–9. http://dx.doi.org/10.1016/j.jconrel.2008.04.020.

      [15] Bender J, Ericson MB, Merclin N, Iani V, Rosen A, Engstrom S, et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release. 2005; 106:350–60. http://dx.doi.org/10.1016/j.jconrel.2005.05.010.

      [16] Scartazzini R, Luisi PL. Organogels from lecithins. J Phys Chem. 1988; 92:829-833. http://dx.doi.org/10.1021/j100314a047.

      [17] Schurtenberger P, Scartazzini R, Magid LJ, Leser ME, Luisi PL. Structural and dynamic properties of polymer-like reverse micelles. J Phys Chem. 1990; 94:3695-3701 http://dx.doi.org/10.1021/j100372a062.

      [18] Martin, A., 1993. Coarse dispersions. In: Martin, A. (Ed.), Physical Pharmacy, fourth ed. William and Wilkins, USA, pp. 496–502.

      [19] Shchipunov Y.A.; Dueerrschmidt T.; Hoffmann H. (2000), Endto end fusion of polymer like micellege in lecithin organogel under the action of an electric field, Langmuir, 16, 297-299. http://dx.doi.org/10.1021/la990810s.

      [20] Shchipunov Y.A.; Dueerrschmidt T.; Hoffmann H.; (1999) Electroheological effects in lecithin organogels with water and glycerol. J. Colloid Interface Science; 212: 390-401. http://dx.doi.org/10.1006/jcis.1998.6046.

      [21] Nasseri A.A.; Aboofazeli R.; Zia H.; and Needham T.E.; (2003) Lecithin stabilize microemulsion. I: Phase behavior studies. Iranian J. Pharm. Res., 2:59-61.

      [22] Willimann H.; Luisi P.L.; (1991) Lecithin organogels as matrix for transdermal transport of drugs. Biochem Biophys Res Commun.; 177: 897-900. http://dx.doi.org/10.1016/0006-291X(91)90622-E.

      [23] Couffin-Hoarau A.C.; Motulsky A.; (2004) Insitu-forming pharmaceutical organogels based on the self-assembly of L-Alanine derivatives. Pharm Res; 21: 454-457. http://dx.doi.org/10.1023/B:PHAM.0000019299.01265.05.

      [24] Kamel A.E.; Sokar M.; Naggar V.; Gamal S.A.; (2002) Chitosan and sodium alginate-based bioadhesive vaginal tablets, AAPS PharmSci.; 4: 1 – 7.

      [25] Mishra D.N.; Gilhotra R.M.; (2008) Design and characterization of bioadhesive in – situ gelling ocular insert of gatifloxacin sesquihydrate. Daru; 16: 1 – 8.

      [26] Vogel (2002) Drug Discovery and Evaluation Pharmacological Assays” 2nd Ed.

      [27] Kukarni S.K. (2007) Hand book of experimental pharmacology 3rd edition, 125-126.

      [28] Laithy H.M. and. Shaboury K.M. F. (2002). “The Development of Cutina Lipogels and Gel Microemulsion for Topical Administration of Fluconazole.” AAPS Pharm Sci. Tech. 3:E35.

      [29] Radomska A.; Dobrucki R.; (2000) the use of some ingredients for microemulsion preparation containing retinol and its esters. International journal of Pharmaceutics, 196, 131-134. http://dx.doi.org/10.1016/S0378-5173(99)00436-6.

      [30] Vinegar R; Schreiber W; Hugo R (1969), Biphasic development of carrageenin oedema in rats. Journal of Pharmacology and Experimental Therapeutics 166, 96-103.

      [31] Vinegar R (1968), Quantitative studies concerning kaolin edema formation in rats. Journal of Pharmacology and Experimental Therapeutics, 161, 389-395.


 

View

Download

Article ID: 5028
 
DOI: 10.14419/ijsw.v3i2.5028




Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.